Clinical outcomes of Descemet's membrane endothelial keratoplasty in eyes with toxic anterior segment syndrome
First Author: N.Gunaydın TURKEY
Co Author(s): N. Tutas Gunaydin B. Kandemir B. Tanyildiz
To evaluate the feasibility and clinical outcomes of Descemet membrane endothelial keratoplasty (DMEK) in eyes with toxic anterior segment syndrome (TASS) after cataract surgery.
Department of Ophthalmology, Dr. Lutfi Kırdar Kartal Traning and Research Hospital, tertiary referral center, Istanbul, Turkey. Turkey.
In this retrospective, interventional case series the clinical outcomes of 10 DMEK procedures for endothelial decompensation due to TASS were analyzed. Main outcome measures were best-corrected visual acuity (BCVA), endothelial cell density(ECD), central corneal thickness (CCT) and postoperative complications.
Mean follow-up time was 21± 4 months. Mean preoperative BCVA was logMAR 2.1 and improved to logMAR 0.67 at 1 year postoperatively. The mean ECD was 2456 ± 197.76 cells/mm2 preoperatively and 1098 ± 217.6 cells/mm2 at 12th months (p=.008). The mean CCT of the patients was 735.42 ± 68.9 preoperatively and 598.28 ± 84.42 months at 12th month (p = .005). The rebubbling rate was 30% (11/24). Secondary glaucoma in 3 eyes (30%) was controlled by medical treatment and Re-DMEK was performed in 3 eyes (30%) who developed graft failure.
Our data provide evidence that DMEK is feasible for the treatment of endothelial decompensation in eyes with TASS.